title: GABAB receptor antagonist CGP46381 inhibits form-deprivation myopia development in guinea pigs.
abstract: The aim was to investigate the effects of the GABAB receptor antagonist, CGP46381, on form-deprivation myopia (FDM) in guinea pigs. Twenty-four guinea pigs had monocular visual deprivation induced using a diffuser for 11 days (day 14 to 25). The deprived eyes were treated with daily subconjunctival injections (100 μl) of either 2% CGP46381, 0.2% CGP46381, or saline or received no injection. The fellow eyes were left untreated. Another six animals received no treatment. At the start and end of the treatment period, ocular refractions were measured using retinoscopy and vitreous chamber depth (VCD) and axial length (AL) using A-scan ultrasound. All of the deprived eyes developed relative myopia (treated versus untreated eyes, P < 0.05). The amount of myopia was significantly affected by the drug treatment (one-way ANOVA, P < 0.0001). The highest dose tested, 2% CGP46381, significantly inhibited myopia development compared to saline (2% CGP46381: -1.08 ± 0.40 D, saline: -4.33 ± 0.67 D, P < 0.01). The majority of these effects were due to less AL (2% CGP46381: 0.03 ± 0.01 mm, saline: 0.13 ± 0.02 mm, P < 0.01) and VCD (2% CGP46381: 0.02 ± 0.01 mm, saline: 0.08 ± 0.01 mm, P < 0.01) elongation. The lower dose tested, 0.2% CGP46381, did not significantly inhibit FDM (P > 0.05). Subconjunctival injections of CGP46381 inhibit FDM development in guinea pigs in a dose-dependent manner.
authors: Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, 4 Gansu Road, Heping District, Tianjin 300020, China ; Department of Ophthalmology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
authors: Zhen-Ying
authors: 0000-0002-6234-8008
authors: ZY
authors: Cheng
authors: The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
authors: Xu-Ping
authors: XP
authors: Wang
authors: School of Optometry and Vision Science, Faculty of Health, and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
authors: Katrina L
authors: KL
authors: Schmid
authors: Tianjin Nankai High School, 22 Nankaisima Road, Nankai District, Tianjin 300100, China.
authors: Yu-Fei
authors: YF
authors: Han
authors: Department of Ophthalmology, The Second People's Hospital of Jinan, Jinan, Shandong 250001, China.
authors: Xu-Guang
authors: XG
authors: Han
authors: Department of Ophthalmology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, China.
authors: Hong-Wei
authors: HW
authors: Tang
authors: Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Hospital, 4 Gansu Road, Heping District, Tianjin 300020, China.
authors: Xin
authors: X
authors: Tang
mesh_terms: D000818:Animals; D058452:Axial Length, Eye / Q000187:drug effects / Q000503:physiopathology; D005556:Form Perception / Q000187:drug effects*; D058788:GABA-B Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D006168:Guinea Pigs; D009216:Myopia / Q000188:drug therapy* / Q000503:physiopathology*; D010721:Phosphinic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D018080:Receptors, GABA-B / Q000378:metabolism*; D012029:Refraction, Ocular / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects / Q000503:physiopathology
chemical_list: D058788:GABA-B Receptor Antagonists; D010721:Phosphinic Acids; D018080:Receptors, GABA-B; C086109:3-aminopropyl-cyclohexylmethylphosphinic acid
references: Clin Exp Pharmacol Physiol. 1999 Nov;26(11):937-40
references: 10561820
references: Exp Eye Res. 2013 Sep;114:35-47
references: 23313151
references: Eur J Pharmacol. 2001 Dec 14;433(1):101-4
references: 11755139
references: Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3933-46
references: 12939312
references: Optom Vis Sci. 2004 Feb;81(2):137-47
references: 15127933
references: Prog Neurobiol. 2004 Jun;73(2):127-50
references: 15201037
references: Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1674-7
references: 2016144
references: Exp Eye Res. 2013 Sep;114:120-7
references: 23528534
references: Invest Ophthalmol Vis Sci. 2013;54(10):6798-805
references: 24045989
references: Physiol Res. 2013 Dec 12;62 Suppl 1:S109-14
references: 24329690
references: Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1939-46
references: 25120102
references: Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10759-63
references: 1660149
references: Prog Brain Res. 1992;90:47-60
references: 1378638
references: Invest Ophthalmol Vis Sci. 1993 Jan;34(1):205-15
references: 8425826
references: Eur J Pharmacol. 1993 Mar 23;233(2-3):179-86
references: 8385620
references: Vis Neurosci. 1993 May-Jun;10(3):447-53
references: 8494798
references: J Physiol. 1995 Jan 15;482 ( Pt 2):363-72
references: 7714827
references: Neurosci Lett. 1995 May 5;190(2):133-6
references: 7644122
references: J Pharmacol Exp Ther. 1995 Sep;274(3):1399-403
references: 7562514
references: Ophthalmic Physiol Opt. 1995 Sep;15(5):351-6
references: 8524553
references: Neuroscience. 1996 Sep;74(2):331-9
references: 8865186
references: Neurosci Res. 1997 Sep;29(1):17-25
references: 9293489
references: J Physiol. 1999 May 1;516 ( Pt 3):711-8
references: 10200420
references: Optom Vis Sci. 1999 Jun;76(6):397-407
references: 10416935
references: Trends Pharmacol Sci. 1999 Oct;20(10):396-9
references: 10498952
references: Neuropharmacology. 2005 Jun;48(7):956-64
references: 15857622
references: Chin Med J (Engl). 2005 Apr 5;118(7):561-6
references: 15861568
references: Vis Neurosci. 2005 May-Jun;22(3):251-61
references: 16079001
references: Vision Res. 2006 Jan;46(1-2):267-83
references: 16139323
references: J Neurophysiol. 2006 Mar;95(3):1881-7
references: 16319205
references: Br J Pharmacol. 2006 Nov;149(5):581-90
references: 16921399
references: Pharmacol Rev. 2008 Sep;60(3):243-60
references: 18790874
references: Optom Vis Sci. 2009 Jan;86(1):E23-30
references: 19104466
references: J Pharmacol Exp Ther. 2009 Feb;328(2):448-57
references: 18984654
references: J Physiol. 2009 May 1;587(Pt 9):1873-9
references: 19153158
references: Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6162-71
references: 20592231
references: Mol Vis. 2011;17:680-92
references: 21403852
references: Ophthalmic Physiol Opt. 2011 Sep;31(5):529-39
references: 21539592
references: Mol Vis. 2011;17:2824-34
references: 22128230
references: Invest Ophthalmol Vis Sci. 2012 Aug;53(9):5827-37
references: 22836762
references: Neurosci Lett. 2013 Feb 28;539:43-7
references: 23384571
references: Exp Eye Res. 2013 May;110:88-95
references: 23474145
references: J Neurosci. 2001 Feb 1;21(3):897-910
references: 11157076